Credits: Canva
As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.
As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."
The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.
The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.
Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.
As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.
A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.
TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."
Credit: Instagram
Marketa Vondrousova, the 2023 Wimbledon singles champion, has been banned from professional sport for four years after refusing an anti-doping test.
According to an independent tribunal, the 26-year-old provided “no compelling justification” for declining to provide a sample after being notified at her home by a doping control officer in December.
“We recognize that this is a significant ban. And the reason for that is that you can’t have an anti-doping system where a player is in a better place by refusing to take a test than they would be by taking the test and testing positive,” said Karen Moorhouse, chief executive of the International Tennis Integrity Agency (ITIA).
“That feeds into the structure of the doping rules that provides for a starting point of a four-year ban for refusing to take a test, the same as a starting point for testing positive,” she added.
The Czech player said in April that she feared for her safety when the officer called and claimed the officer had failed to follow protocol.
Vondrousova reached the French Open final in 2019, won an Olympic silver medal in 2021, and achieved a career-high ranking of No. 6.
“I have never doped, I have never had a positive test. Throughout my entire career, I have undergone countless anti-doping controls and have always stepped onto the court with a clear conscience. I cannot say what comes next. For the first time in my life, I do not have a plan,” she said in a statement.
She is suspended from all professional events until June 21, 2030, but has the right to appeal the decision to the Court of Arbitration for Sport (CAS).
According to Vondrousova, the doping control officer did not adhere to the rules by approaching her outside the hour she had designated under the whereabouts rules. During the hearing, Vondrousova said stress and poor mental health had affected her decision-making, in addition to her safety concerns.
Also read: Why Sleeping Pill Addiction Is Common Among Football Players
Doping control (testing) is one tool that Anti-Doping Organizations (ADOs) use to level the playing field and protect clean sport.
As per the World Anti-Doping Agency (WADA), athletes playing at the national or international level can be subject to doping control and can be tested anytime or anywhere.
Credit: iStock
Amid a red alert for a severe heatwave in the UK, the Met Office has also warned of a "pollen bomb" that could significantly affect people with hay fever.
The forecaster said there is no evidence that pollen levels are worse this year, but symptoms may feel more severe due to a combination of high pollen counts and exposure to multiple pollen types.
A 2026 Lancet Countdown in Europe study found that climate change is altering the flowering seasons of plants that release allergenic pollen.
“The combination of the fairly breezy and dry weather is going to bring a lot of pollen into the air this week and for the coming weeks,” Alastair Culham, Professor of Botany at the University of Reading, told The Independent.
“We've seen quite a mixed year so far, a very warm, dry spring which brought pollen on early, and then a series of wet weather which has allowed the grasses to grow exceptionally well. Now the weather has warmed and dried, those grasses are going into flower and the level of pollen from grass is phenomenally high,” he added.
Also read: UK Issues Red Heat-Health Alert: How to Protect Yourself From Extreme Heat
Rising temperatures, expected to exceed 30°C on several days this week, are causing trees and grasses to release large amounts of pollen into the air.
“Hay fever symptoms usually appear when the pollen count, which is a measure of the number of grains of pollen in one cubic meter of air, exceeds 50,” the Met Office said.
The agency noted that weather conditions influence how much pollen is released and spread. Humid and windy conditions help pollen travel, while rain can clear it from the air. On sunny days, pollen levels are typically highest in the early evening.
Read To Know: No Women Aged 20-24 Died of Cervical Cancer in England Over Five Years, Thanks to HPV Vaccine
The Met Office has warned that grass pollen will remain at high levels across England and Wales, with Yorkshire, the Midlands and the North West expected to experience very high counts.

Pollen levels are forecast to be very high across England on June 24, with temperatures reaching around 38°C in some areas.
Northern Ireland and Scotland are also expected to experience medium to high pollen levels throughout the week.
Read More: WHO Sounds Alarm on Europe's Extreme Heat: Here's How Hot It Could Get Across Countries
Hay fever is a common allergy that causes sneezing, coughing and itchy eyes.
According to Allergy UK, one in four adults and one in eight children suffer from allergic rhinitis, the medical term for hay fever. Research suggests the number of sufferers is increasing each year.
The Lancet study found that hay fever sufferers now experience symptoms for up to two weeks longer than they did in the 1990s due to climate change.
According to the UK NHS, hay fever can last for weeks or months, unlike a cold, which usually resolves within one to two weeks. While there is no cure, symptoms can be managed when pollen levels are high.
Credit: https://johnleeindia.com/
More than 11,000 bottles of the blood pressure medication Chlorthalidone, manufactured in India, have been recalled in the United States, according to the Food and Drug Administration (FDA). This is the second India-made blood pressure drug to be recalled in over a month.
Mumbai-based manufacturer Inventia Healthcare Limited recalled the prescription-only Chlorthalidone Tablets USP, 25 mg on June 5 due to "failed dissolution specifications." This means that the tablets may not break down correctly in the body. The drug is sold under several brand names, including Thalitone and Hygroton, and is distributed in America by New Jersey-based Rising Pharma Holdings.
Also read: Robert F. Kennedy Jr. Launches Reforms To Speed Up Early Drug Research In US
Chlorthalidone is a diuretic, or "water pill," prescribed to treat high blood pressure and fluid retention associated with conditions such as congestive heart failure, kidney disease, and liver disease.
It works by helping the kidneys eliminate excess water and salt through urine.
The FDA has not yet classified the recall or detailed the potential health consequences for patients.
Dissolution refers to the process by which a tablet breaks down and releases its active ingredient into the body after it is taken.
A dissolution failure means that, during regulatory testing, the tablets did not dissolve as required. As a result, the active ingredient may not be released properly, potentially reducing the amount of medicine that reaches the bloodstream and works as intended, according to Cardiovascular Business..
Dissolution problems can arise from several factors, including poor formulation design, manufacturing process issues, low-quality raw materials, or stability issues that affect the product over time.
Also read: US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine
According to the FDA, 11,460 bottles of Chlorthalidone are included in the recall and carry an expiration date of April 2027.
The recall affects:
Read More: 4 Indian States Roll Out IV Iron Therapy To Curb Anemia In Pregnant Women: How It Works
The recall follows another FDA recall announced on May 5 involving Amlodipine and Olmesartan Medoxomil Tablets (5 mg/40 mg), another prescription blood pressure medication.
A total of 15,696 bottles were recalled due to "failed dissolution specifications: Olmesartan Medoxomil content below specifications."
The medication was also manufactured by Alkem Laboratories Ltd. in India and distributed by Ascend Laboratories, LLC, Parsippany, New Jersey. The recalled bottles carry an expiration date of October 31, 2027.
Both recalls were issued nationwide.
The latest recall follows a separate large-scale blood pressure medication recall in October, when manufacturers recalled more than 500,000 bottles of Prazosin Hydrochloride due to contamination concerns.
That recall involved potential contamination with unsafe levels of a cancer-causing chemical, prompting the manufacturer to advise patients to consult their physicians or pharmacists.
© 2024 Bennett, Coleman & Company Limited